CUTISS granted U.S. patent for disposable hydrogel compression system in skin tissue engineering

CUTISS has been granted a new patent in the United States for a disposable system and method used in the preparation of compressed hydrogels for tissue engineering applications.

The patent (U.S. Patent No. 12,564,662 B2), titled “Disposable system and method for preparing a compressed hydrogel”, protects a fully disposable system for casting, polymerizing and compressing a hydrogel, as well as methods for producing a scaffold for the generation of artificial tissue products, including skin grafts. The patent was granted on March 3, 2026, and is assigned to CUTISS AG, Schlieren.

The patented invention relates to a core part of the tissue engineering process by enabling the preparation of compressed hydrogels in a fully disposable format. According to the patent, this approach is designed to reduce contamination risk, simplify workflow, lower production complexity and support improved quality and scalability in graft manufacturing.

This new U.S. patent further strengthens CUTISS’ intellectual property portfolio in regenerative medicine and tissue bioengineering. It also supports the company’s broader strategy to industrialize personalized skin tissue therapy through robust, standardized and scalable manufacturing approaches for denovoSkin™, CUTISS’ lead product currently in late-stage clinical development in Switzerland and the European Union.

denovoSkin™ is currently in Phase 3 clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA.